Tylenol With Naproxen (acetaminophen, naproxen sodium)

Where it stands

According to the records, the FDA approved Tylenol With Naproxen (acetaminophen, naproxen sodium) on 2026-07-24. The sponsor is Kenvue Brands, the application is NDA219962, and the dosage form is a tablet. The records classify the product as a new combination and cite an official source for the approval.

The records do not give an indication, a therapeutic area, or the intended population. They also do not say whether the product is prescription or over-the-counter, or give any strength or dosing. This analysis therefore cannot describe the approved use or labeling. The label and approval letter should be checked directly for those details.

The CHMP opinion date is blank. That is expected for a US-only record, since the CHMP is the EMA's scientific committee and plays no part in an FDA approval. The records show no EU filing or opinion.

Regulatory pathway and designations

The product was approved under a New Drug Application (NDA219962), the standard US route for marketing authorization of a drug. The only designation recorded is "New combination". In FDA approval listings, this generally means a product combining active ingredients that were each previously approved, but not previously marketed together in this combination. It does not mean a new active ingredient.

The records do not state the specific NDA pathway, such as a full 505(b)(1) application or a 505(b)(2) application relying partly on existing data. They also do not say what clinical or bioequivalence data supported approval. No expedited designations (priority review, fast track, breakthrough) and no exclusivity are recorded, and none should be assumed.

The records contain a single milestone, the approval itself. There is no information on submission date, review timeline, advisory committee activity, or any PDUFA goal date.

Safety and pharmacovigilance

The records contain no safety data, boxed warnings, contraindications, risk management requirements, or postmarketing commitments for this product. Nothing here supports a product-specific safety assessment.

As general background only, not drawn from the records: naproxen is an NSAID, and NSAID labeling typically carries class warnings on cardiovascular thrombotic events and gastrointestinal bleeding, ulceration, and perforation. Acetaminophen labeling typically addresses hepatotoxicity and cumulative daily dose across products. Whether and how these appear in the approved label for this combination is not confirmed by the records and should be verified against the final labeling.

Pharmacovigilance for a marketed US product normally includes adverse event reporting by the sponsor under FDA requirements. Any product-specific obligations are not documented in the records.

What to watch

The first step is to obtain the approved label and approval letter. These will confirm the indication, the Rx or OTC status, the dosing, the warnings, and any postmarketing requirements. None of these are in the records.

Other points to monitor are the commercial launch timing and any labeling updates after approval. The records give no information on either, and none is implied. Teams tracking the broader market should also note that the records show no ex-US regulatory activity for this product.